Mary Weiser-Evans
Concepts (427)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocytes, Smooth Muscle | 22 | 2026 | 271 | 4.620 |
Why?
| | Muscle, Smooth, Vascular | 26 | 2026 | 450 | 4.260 |
Why?
| | PTEN Phosphohydrolase | 14 | 2025 | 165 | 3.750 |
Why?
| | Vascular Remodeling | 8 | 2022 | 209 | 2.450 |
Why?
| | Atherosclerosis | 4 | 2023 | 409 | 2.090 |
Why?
| | Kruppel-Like Transcription Factors | 3 | 2026 | 83 | 2.010 |
Why?
| | Stem Cells | 7 | 2026 | 630 | 1.700 |
Why?
| | Plaque, Atherosclerotic | 2 | 2023 | 61 | 1.510 |
Why?
| | Myofibroblasts | 4 | 2026 | 149 | 1.260 |
Why?
| | Angiotensin II | 4 | 2026 | 102 | 1.210 |
Why?
| | Adventitia | 2 | 2022 | 42 | 1.200 |
Why?
| | Fibrosis | 13 | 2026 | 561 | 1.200 |
Why?
| | Lung Neoplasms | 19 | 2023 | 2667 | 0.910 |
Why?
| | Vascular System Injuries | 3 | 2023 | 81 | 0.900 |
Why?
| | Mice | 44 | 2026 | 18355 | 0.900 |
Why?
| | Cell Proliferation | 18 | 2021 | 2514 | 0.830 |
Why?
| | Cell Differentiation | 11 | 2026 | 2050 | 0.810 |
Why?
| | Neointima | 4 | 2022 | 18 | 0.780 |
Why?
| | Animals | 64 | 2026 | 38097 | 0.750 |
Why?
| | Hypercholesterolemia | 1 | 2023 | 95 | 0.740 |
Why?
| | Tunica Intima | 5 | 2010 | 78 | 0.730 |
Why?
| | Spinocerebellar Ataxias | 1 | 2022 | 6 | 0.730 |
Why?
| | Mice, Knockout | 17 | 2026 | 3130 | 0.730 |
Why?
| | Galectin 3 | 1 | 2022 | 21 | 0.720 |
Why?
| | Myocardium | 2 | 2026 | 935 | 0.680 |
Why?
| | Mice, Inbred C57BL | 23 | 2026 | 5992 | 0.670 |
Why?
| | Heart-Assist Devices | 4 | 2022 | 568 | 0.670 |
Why?
| | Cells, Cultured | 20 | 2026 | 4151 | 0.660 |
Why?
| | DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2020 | 16 | 0.630 |
Why?
| | Serum Response Factor | 3 | 2016 | 33 | 0.610 |
Why?
| | Carotid Artery Injuries | 5 | 2010 | 39 | 0.600 |
Why?
| | Coronary Restenosis | 1 | 2019 | 22 | 0.590 |
Why?
| | Chemokine CXCL12 | 2 | 2011 | 86 | 0.590 |
Why?
| | Cyclin D1 | 1 | 2019 | 64 | 0.590 |
Why?
| | Coronary Vessels | 2 | 2018 | 246 | 0.580 |
Why?
| | High-Throughput Screening Assays | 1 | 2020 | 177 | 0.550 |
Why?
| | Arteries | 4 | 2022 | 261 | 0.520 |
Why?
| | Disease Models, Animal | 18 | 2026 | 4568 | 0.510 |
Why?
| | Vascular Diseases | 1 | 2019 | 252 | 0.500 |
Why?
| | Rats | 20 | 2019 | 5585 | 0.490 |
Why?
| | Heparan Sulfate Proteoglycans | 4 | 2003 | 23 | 0.480 |
Why?
| | Tumor Microenvironment | 8 | 2021 | 735 | 0.480 |
Why?
| | Mice, Transgenic | 9 | 2020 | 2191 | 0.470 |
Why?
| | Gene Expression Regulation | 6 | 2024 | 2601 | 0.460 |
Why?
| | PPAR gamma | 7 | 2019 | 182 | 0.450 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 7 | 2023 | 1191 | 0.420 |
Why?
| | Cell Division | 8 | 2004 | 757 | 0.420 |
Why?
| | Hypertension, Pulmonary | 5 | 2023 | 1957 | 0.400 |
Why?
| | Hypertension | 1 | 2022 | 1276 | 0.400 |
Why?
| | MicroRNAs | 2 | 2017 | 686 | 0.390 |
Why?
| | Signal Transduction | 18 | 2019 | 5223 | 0.390 |
Why?
| | Acute Kidney Injury | 5 | 2023 | 874 | 0.390 |
Why?
| | Hyperplasia | 5 | 2020 | 177 | 0.390 |
Why?
| | Protein Kinases | 4 | 2014 | 312 | 0.370 |
Why?
| | Phenotype | 11 | 2026 | 3170 | 0.340 |
Why?
| | Transforming Growth Factor beta1 | 3 | 2023 | 177 | 0.340 |
Why?
| | Bone Marrow Cells | 2 | 2011 | 322 | 0.330 |
Why?
| | Ureteral Obstruction | 3 | 2021 | 63 | 0.320 |
Why?
| | Cell Movement | 5 | 2012 | 961 | 0.320 |
Why?
| | Kidney | 6 | 2021 | 1496 | 0.310 |
Why?
| | Muscle, Smooth | 2 | 2023 | 153 | 0.310 |
Why?
| | Macrophages | 4 | 2021 | 1507 | 0.300 |
Why?
| | Autocrine Communication | 2 | 2014 | 38 | 0.300 |
Why?
| | Phospholipases A2, Cytosolic | 1 | 2009 | 4 | 0.290 |
Why?
| | Cell Dedifferentiation | 3 | 2016 | 32 | 0.290 |
Why?
| | Male | 27 | 2026 | 73003 | 0.280 |
Why?
| | Platelet-Derived Growth Factor | 4 | 2020 | 85 | 0.280 |
Why?
| | Group IV Phospholipases A2 | 3 | 2017 | 46 | 0.280 |
Why?
| | Cisplatin | 3 | 2020 | 345 | 0.270 |
Why?
| | Carcinoma, Lewis Lung | 2 | 2019 | 16 | 0.260 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2004 | 36 | 0.260 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 4 | 2019 | 35 | 0.260 |
Why?
| | Proteins | 2 | 2006 | 1023 | 0.260 |
Why?
| | Proto-Oncogene Proteins c-akt | 7 | 2014 | 440 | 0.250 |
Why?
| | Heart Failure | 4 | 2023 | 2326 | 0.250 |
Why?
| | Rats, Sprague-Dawley | 9 | 2016 | 2525 | 0.240 |
Why?
| | Actins | 3 | 2018 | 426 | 0.240 |
Why?
| | Antigens, Ly | 1 | 2026 | 46 | 0.240 |
Why?
| | Nuclear Proteins | 2 | 2023 | 740 | 0.240 |
Why?
| | Proto-Oncogene Proteins | 3 | 2004 | 625 | 0.240 |
Why?
| | Hypoxia | 2 | 2013 | 1199 | 0.240 |
Why?
| | TOR Serine-Threonine Kinases | 5 | 2014 | 456 | 0.230 |
Why?
| | Acetyltransferases | 1 | 2006 | 27 | 0.230 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2003 | 431 | 0.230 |
Why?
| | Humans | 35 | 2026 | 145763 | 0.230 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 2 | 2019 | 235 | 0.230 |
Why?
| | Adenocarcinoma | 5 | 2017 | 926 | 0.220 |
Why?
| | RNA Interference | 5 | 2014 | 475 | 0.220 |
Why?
| | Embryonic Development | 1 | 2006 | 125 | 0.220 |
Why?
| | Inflammation | 4 | 2023 | 2883 | 0.220 |
Why?
| | Endothelial Cells | 2 | 2022 | 877 | 0.220 |
Why?
| | Fibromuscular Dysplasia | 1 | 2024 | 8 | 0.210 |
Why?
| | Myeloid Cells | 2 | 2019 | 147 | 0.210 |
Why?
| | Gene Expression | 3 | 2014 | 1478 | 0.210 |
Why?
| | Phosphatidylinositol 3-Kinases | 4 | 2010 | 383 | 0.210 |
Why?
| | Aortic Valve | 2 | 2025 | 364 | 0.210 |
Why?
| | Ribosomal Protein S6 | 1 | 2004 | 18 | 0.210 |
Why?
| | Inflammation Mediators | 2 | 2021 | 507 | 0.200 |
Why?
| | Corn Oil | 1 | 2023 | 5 | 0.200 |
Why?
| | Receptors, LDL | 1 | 2023 | 53 | 0.200 |
Why?
| | Azotemia | 1 | 2023 | 13 | 0.190 |
Why?
| | Proprotein Convertase 9 | 1 | 2023 | 87 | 0.190 |
Why?
| | Phosphorylation | 6 | 2019 | 1708 | 0.190 |
Why?
| | Lipoxygenase Inhibitors | 2 | 2021 | 34 | 0.190 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 167 | 0.190 |
Why?
| | Rejuvenation | 1 | 2022 | 18 | 0.180 |
Why?
| | Disease Progression | 7 | 2019 | 2865 | 0.180 |
Why?
| | Polycystic Kidney Diseases | 2 | 2019 | 71 | 0.180 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2021 | 17 | 0.180 |
Why?
| | Aortic Valve Insufficiency | 1 | 2022 | 43 | 0.180 |
Why?
| | Aortic Valve Stenosis | 1 | 2025 | 256 | 0.180 |
Why?
| | Gene Regulatory Networks | 1 | 2024 | 318 | 0.180 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2020 | 266 | 0.180 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2021 | 20 | 0.180 |
Why?
| | Cytokines | 4 | 2021 | 2069 | 0.170 |
Why?
| | DNA Helicases | 1 | 2023 | 136 | 0.170 |
Why?
| | Fibroblasts | 2 | 2024 | 1027 | 0.170 |
Why?
| | Nephritis | 1 | 2021 | 22 | 0.170 |
Why?
| | Extracellular Matrix | 4 | 2021 | 562 | 0.170 |
Why?
| | Assisted Circulation | 1 | 2021 | 26 | 0.170 |
Why?
| | Dual-Specificity Phosphatases | 1 | 2021 | 10 | 0.170 |
Why?
| | Cholesterol | 1 | 2023 | 408 | 0.170 |
Why?
| | Adaptive Immunity | 2 | 2023 | 167 | 0.170 |
Why?
| | Metformin | 2 | 2023 | 329 | 0.170 |
Why?
| | Zebrafish | 1 | 2006 | 532 | 0.170 |
Why?
| | Transcription Factors | 4 | 2023 | 1736 | 0.170 |
Why?
| | Promoter Regions, Genetic | 5 | 2020 | 1247 | 0.170 |
Why?
| | Cell Line, Tumor | 9 | 2019 | 3551 | 0.160 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2021 | 149 | 0.160 |
Why?
| | Protein Kinase Inhibitors | 3 | 2023 | 981 | 0.160 |
Why?
| | Blotting, Western | 3 | 2019 | 1184 | 0.160 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2023 | 248 | 0.160 |
Why?
| | Jugular Veins | 1 | 2020 | 42 | 0.160 |
Why?
| | Aortic Diseases | 1 | 2021 | 125 | 0.160 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2017 | 1146 | 0.150 |
Why?
| | Intestines | 1 | 2023 | 354 | 0.150 |
Why?
| | Female | 17 | 2024 | 79035 | 0.150 |
Why?
| | Homeostasis | 2 | 2022 | 644 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2019 | 198 | 0.150 |
Why?
| | Arachidonate 5-Lipoxygenase | 2 | 2019 | 37 | 0.150 |
Why?
| | Wound Healing | 1 | 2022 | 355 | 0.150 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2020 | 126 | 0.150 |
Why?
| | GATA4 Transcription Factor | 1 | 2019 | 19 | 0.150 |
Why?
| | Kidney Tubules | 2 | 2019 | 118 | 0.150 |
Why?
| | Crohn Disease | 1 | 2023 | 260 | 0.150 |
Why?
| | Myocytes, Cardiac | 2 | 2014 | 546 | 0.150 |
Why?
| | Neovascularization, Physiologic | 1 | 2000 | 193 | 0.140 |
Why?
| | Azacitidine | 1 | 2020 | 157 | 0.140 |
Why?
| | Chromatin | 1 | 2023 | 553 | 0.140 |
Why?
| | Catheterization | 4 | 2004 | 184 | 0.140 |
Why?
| | Pulmonary Artery | 3 | 2021 | 1129 | 0.140 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 212 | 0.140 |
Why?
| | AMP-Activated Protein Kinases | 2 | 2023 | 192 | 0.140 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2020 | 364 | 0.140 |
Why?
| | Flow Cytometry | 2 | 2019 | 1165 | 0.140 |
Why?
| | Bone Marrow | 2 | 2017 | 307 | 0.140 |
Why?
| | Mice, Knockout, ApoE | 1 | 2018 | 11 | 0.140 |
Why?
| | Epigenesis, Genetic | 1 | 2023 | 693 | 0.140 |
Why?
| | Metabolome | 1 | 2021 | 391 | 0.130 |
Why?
| | Sirolimus | 2 | 2014 | 282 | 0.130 |
Why?
| | Heart Ventricles | 2 | 2021 | 756 | 0.130 |
Why?
| | Interleukin-33 | 1 | 2017 | 45 | 0.130 |
Why?
| | Trans-Activators | 1 | 2020 | 396 | 0.130 |
Why?
| | Skin | 1 | 2022 | 754 | 0.130 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2019 | 220 | 0.130 |
Why?
| | Receptors, Complement | 1 | 2017 | 123 | 0.130 |
Why?
| | Epithelial Cells | 3 | 2019 | 1134 | 0.120 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 426 | 0.120 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2021 | 923 | 0.120 |
Why?
| | Gene Deletion | 2 | 2014 | 392 | 0.120 |
Why?
| | Ventricular Remodeling | 2 | 2023 | 278 | 0.120 |
Why?
| | Immunotherapy | 2 | 2018 | 667 | 0.120 |
Why?
| | Interferon-gamma | 1 | 2019 | 784 | 0.110 |
Why?
| | Cell Cycle Proteins | 1 | 2019 | 630 | 0.110 |
Why?
| | Dinoprostone | 3 | 2016 | 180 | 0.110 |
Why?
| | Energy Metabolism | 1 | 2021 | 935 | 0.110 |
Why?
| | B7-H1 Antigen | 1 | 2017 | 244 | 0.110 |
Why?
| | Focal Adhesion Kinase 1 | 3 | 2003 | 32 | 0.110 |
Why?
| | Autophagy | 2 | 2014 | 291 | 0.110 |
Why?
| | NF-kappa B | 2 | 2010 | 667 | 0.110 |
Why?
| | Intracellular Signaling Peptides and Proteins | 3 | 2019 | 457 | 0.110 |
Why?
| | Retinoid X Receptors | 1 | 2014 | 42 | 0.110 |
Why?
| | Complement Activation | 1 | 2017 | 399 | 0.100 |
Why?
| | Interleukin-6 | 3 | 2023 | 779 | 0.100 |
Why?
| | Aorta | 3 | 2004 | 440 | 0.100 |
Why?
| | Pleural Neoplasms | 1 | 2014 | 31 | 0.100 |
Why?
| | Culture Media, Serum-Free | 2 | 2004 | 42 | 0.100 |
Why?
| | Gene Amplification | 1 | 2014 | 118 | 0.100 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2014 | 58 | 0.100 |
Why?
| | Mesothelioma | 1 | 2014 | 52 | 0.100 |
Why?
| | Leukotrienes | 1 | 2013 | 28 | 0.100 |
Why?
| | Kidney Diseases | 1 | 2017 | 426 | 0.100 |
Why?
| | Paracrine Communication | 1 | 2014 | 67 | 0.100 |
Why?
| | Eicosanoids | 1 | 2013 | 58 | 0.100 |
Why?
| | Oligonucleotides, Antisense | 2 | 2004 | 120 | 0.100 |
Why?
| | RNA | 1 | 2019 | 912 | 0.100 |
Why?
| | Myocardial Contraction | 1 | 2014 | 293 | 0.090 |
Why?
| | Monocytes | 1 | 2016 | 539 | 0.090 |
Why?
| | Iloprost | 2 | 2010 | 45 | 0.090 |
Why?
| | Macrophage Activation | 1 | 2014 | 181 | 0.090 |
Why?
| | Macrophages, Alveolar | 1 | 2016 | 373 | 0.090 |
Why?
| | MAP Kinase Signaling System | 3 | 2021 | 308 | 0.090 |
Why?
| | Up-Regulation | 2 | 2008 | 848 | 0.090 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2014 | 143 | 0.090 |
Why?
| | Tumor Burden | 3 | 2020 | 325 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2019 | 668 | 0.090 |
Why?
| | Immunohistochemistry | 4 | 2021 | 1723 | 0.090 |
Why?
| | Lipocalin-2 | 2 | 2023 | 80 | 0.090 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 956 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2014 | 474 | 0.080 |
Why?
| | Splenectomy | 1 | 2011 | 61 | 0.080 |
Why?
| | Protein Processing, Post-Translational | 2 | 2004 | 473 | 0.080 |
Why?
| | T-Lymphocytes | 2 | 2017 | 1997 | 0.080 |
Why?
| | Cyclooxygenase 2 | 2 | 2010 | 167 | 0.080 |
Why?
| | Histone Deacetylases | 1 | 2012 | 207 | 0.080 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2012 | 218 | 0.080 |
Why?
| | Green Fluorescent Proteins | 1 | 2011 | 407 | 0.080 |
Why?
| | Frizzled Receptors | 1 | 2010 | 25 | 0.080 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 3 | 2015 | 264 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2024 | 3634 | 0.070 |
Why?
| | RNA, Small Interfering | 2 | 2010 | 638 | 0.070 |
Why?
| | Receptors, Epoprostenol | 1 | 2008 | 5 | 0.070 |
Why?
| | TRPP Cation Channels | 2 | 2019 | 74 | 0.070 |
Why?
| | Reperfusion Injury | 1 | 2011 | 292 | 0.070 |
Why?
| | Glycoproteins | 1 | 2010 | 354 | 0.070 |
Why?
| | Lung Injury | 1 | 2011 | 249 | 0.070 |
Why?
| | Epoprostenol | 1 | 2008 | 132 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2013 | 2933 | 0.070 |
Why?
| | Antineoplastic Agents | 2 | 2017 | 2219 | 0.070 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2010 | 231 | 0.070 |
Why?
| | Adenosine Triphosphate | 2 | 2014 | 500 | 0.070 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2010 | 337 | 0.070 |
Why?
| | Receptors, CXCR4 | 1 | 2008 | 91 | 0.070 |
Why?
| | Hematopoietic Stem Cells | 1 | 2011 | 435 | 0.060 |
Why?
| | Culture Media, Conditioned | 2 | 2014 | 112 | 0.060 |
Why?
| | Gene Silencing | 2 | 2019 | 202 | 0.060 |
Why?
| | Biomarkers | 4 | 2023 | 4302 | 0.060 |
Why?
| | Neoplasm Metastasis | 1 | 2009 | 688 | 0.060 |
Why?
| | Apoptosis | 3 | 2020 | 2443 | 0.060 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 298 | 0.060 |
Why?
| | Antihypertensive Agents | 1 | 2010 | 521 | 0.060 |
Why?
| | RNA, Messenger | 5 | 2010 | 2805 | 0.060 |
Why?
| | Mitogens | 1 | 2005 | 55 | 0.060 |
Why?
| | Neoplasm Transplantation | 2 | 2016 | 246 | 0.060 |
Why?
| | Middle Aged | 4 | 2024 | 36302 | 0.060 |
Why?
| | Acetylation | 1 | 2006 | 259 | 0.060 |
Why?
| | Protein Subunits | 1 | 2006 | 229 | 0.050 |
Why?
| | Animals, Genetically Modified | 1 | 2006 | 247 | 0.050 |
Why?
| | Mutation | 3 | 2023 | 4090 | 0.050 |
Why?
| | Gene Knockout Techniques | 2 | 2015 | 119 | 0.050 |
Why?
| | Pyrimidines | 2 | 2023 | 530 | 0.050 |
Why?
| | Pregnancy | 2 | 2016 | 7215 | 0.050 |
Why?
| | Enzyme Inhibitors | 2 | 2007 | 821 | 0.050 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2015 | 174 | 0.050 |
Why?
| | Cell Size | 2 | 2005 | 93 | 0.050 |
Why?
| | Chromones | 1 | 2004 | 43 | 0.050 |
Why?
| | Basement Membrane | 1 | 2003 | 32 | 0.050 |
Why?
| | Gene Expression Profiling | 3 | 2016 | 1777 | 0.050 |
Why?
| | Androstadienes | 1 | 2004 | 77 | 0.050 |
Why?
| | Acute-Phase Reaction | 1 | 2023 | 37 | 0.050 |
Why?
| | Embryo, Mammalian | 2 | 2003 | 234 | 0.050 |
Why?
| | Glycosaminoglycans | 1 | 2003 | 79 | 0.050 |
Why?
| | Tenascin | 1 | 2003 | 15 | 0.050 |
Why?
| | Furosemide | 1 | 2023 | 37 | 0.050 |
Why?
| | Peroxidases | 1 | 2003 | 28 | 0.050 |
Why?
| | Morpholines | 1 | 2004 | 130 | 0.050 |
Why?
| | Peroxidase | 2 | 2015 | 168 | 0.050 |
Why?
| | Fibronectins | 1 | 2003 | 136 | 0.050 |
Why?
| | Transfection | 3 | 2014 | 927 | 0.050 |
Why?
| | Murinae | 1 | 2022 | 6 | 0.050 |
Why?
| | Acrylamides | 1 | 2023 | 74 | 0.050 |
Why?
| | Metalloproteases | 1 | 2022 | 42 | 0.050 |
Why?
| | Ileum | 1 | 2023 | 112 | 0.050 |
Why?
| | Coculture Techniques | 2 | 2014 | 247 | 0.040 |
Why?
| | Aniline Compounds | 1 | 2023 | 120 | 0.040 |
Why?
| | Cadherins | 2 | 2016 | 200 | 0.040 |
Why?
| | Matrix Metalloproteinases, Secreted | 1 | 2021 | 12 | 0.040 |
Why?
| | ADAMTS4 Protein | 1 | 2021 | 16 | 0.040 |
Why?
| | Long Term Adverse Effects | 1 | 2021 | 13 | 0.040 |
Why?
| | Cell Line | 2 | 2018 | 2823 | 0.040 |
Why?
| | DNA Replication | 1 | 2003 | 249 | 0.040 |
Why?
| | Adult | 3 | 2024 | 40872 | 0.040 |
Why?
| | Aorta, Thoracic | 1 | 2003 | 286 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 93 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2003 | 666 | 0.040 |
Why?
| | Aged | 2 | 2018 | 26215 | 0.040 |
Why?
| | Ventricular Function, Right | 1 | 2023 | 297 | 0.040 |
Why?
| | Major Histocompatibility Complex | 1 | 2021 | 233 | 0.040 |
Why?
| | Vasoconstrictor Agents | 1 | 2021 | 150 | 0.040 |
Why?
| | Butadienes | 1 | 2020 | 33 | 0.040 |
Why?
| | Blood Urea Nitrogen | 1 | 2020 | 53 | 0.040 |
Why?
| | Contractile Proteins | 1 | 2000 | 13 | 0.040 |
Why?
| | Leukocytes | 1 | 2021 | 296 | 0.040 |
Why?
| | Cell Fusion | 1 | 2000 | 48 | 0.040 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2000 | 48 | 0.040 |
Why?
| | Thiazolidinediones | 2 | 2011 | 143 | 0.040 |
Why?
| | Neoplasms | 1 | 2015 | 2913 | 0.040 |
Why?
| | NADH, NADPH Oxidoreductases | 1 | 2019 | 23 | 0.040 |
Why?
| | Enzyme Activation | 2 | 2014 | 762 | 0.040 |
Why?
| | Growth Substances | 1 | 2000 | 138 | 0.040 |
Why?
| | Liver | 2 | 2023 | 1899 | 0.040 |
Why?
| | Genes, Tumor Suppressor | 1 | 2000 | 85 | 0.040 |
Why?
| | Cloning, Molecular | 1 | 2000 | 538 | 0.040 |
Why?
| | Suppressor of Cytokine Signaling 1 Protein | 1 | 2019 | 12 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2023 | 765 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2023 | 635 | 0.040 |
Why?
| | Mesoderm | 1 | 2020 | 147 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2019 | 38 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2020 | 125 | 0.040 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2003 | 414 | 0.040 |
Why?
| | Tropoelastin | 1 | 1999 | 11 | 0.040 |
Why?
| | Receptors, Leukotriene | 1 | 2019 | 13 | 0.040 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2019 | 55 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 442 | 0.040 |
Why?
| | Indoles | 1 | 2023 | 507 | 0.040 |
Why?
| | Nitriles | 1 | 2020 | 211 | 0.040 |
Why?
| | Luciferases | 2 | 2010 | 154 | 0.040 |
Why?
| | Proteoglycans | 1 | 1999 | 112 | 0.030 |
Why?
| | Pyridones | 1 | 2020 | 209 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 254 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2003 | 910 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 979 | 0.030 |
Why?
| | Antibodies, Blocking | 1 | 2017 | 37 | 0.030 |
Why?
| | Tumor Cells, Cultured | 2 | 2010 | 887 | 0.030 |
Why?
| | Complement C3d | 1 | 2017 | 62 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2023 | 883 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 442 | 0.030 |
Why?
| | Complement C3 | 1 | 2017 | 187 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 2017 | 265 | 0.030 |
Why?
| | Arachidonic Acid | 1 | 2016 | 102 | 0.030 |
Why?
| | Myocardial Ischemia | 1 | 2018 | 285 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 440 | 0.030 |
Why?
| | Immunocompetence | 1 | 2016 | 46 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 212 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2024 | 2399 | 0.030 |
Why?
| | Lymphocyte Depletion | 1 | 2015 | 132 | 0.030 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2015 | 153 | 0.030 |
Why?
| | Organ Culture Techniques | 2 | 2007 | 154 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2015 | 156 | 0.030 |
Why?
| | Homozygote | 1 | 2015 | 199 | 0.030 |
Why?
| | Chemokines | 1 | 2016 | 217 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 337 | 0.030 |
Why?
| | Caspase 3 | 1 | 2015 | 242 | 0.030 |
Why?
| | Time Factors | 2 | 2017 | 7133 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2018 | 544 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-sis | 2 | 2005 | 39 | 0.030 |
Why?
| | Tetrahydronaphthalenes | 1 | 2014 | 34 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 936 | 0.030 |
Why?
| | Intracellular Space | 1 | 2014 | 64 | 0.030 |
Why?
| | Heart | 1 | 2018 | 626 | 0.030 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2014 | 20 | 0.030 |
Why?
| | Chemokine CCL2 | 1 | 2014 | 112 | 0.030 |
Why?
| | Pyridazines | 1 | 2014 | 57 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 508 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2016 | 228 | 0.030 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2014 | 94 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 198 | 0.030 |
Why?
| | Clone Cells | 1 | 2014 | 263 | 0.030 |
Why?
| | Ventricular Myosins | 1 | 2014 | 39 | 0.030 |
Why?
| | Microfilament Proteins | 1 | 2014 | 135 | 0.020 |
Why?
| | Cardiomegaly | 1 | 2014 | 174 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2014 | 221 | 0.020 |
Why?
| | Integrases | 1 | 2014 | 122 | 0.020 |
Why?
| | Imidazoles | 1 | 2014 | 247 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2013 | 175 | 0.020 |
Why?
| | Femoral Artery | 1 | 2014 | 190 | 0.020 |
Why?
| | Mice, Nude | 1 | 2014 | 680 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2016 | 529 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2022 | 1791 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1329 | 0.020 |
Why?
| | Capillary Leak Syndrome | 1 | 2011 | 12 | 0.020 |
Why?
| | Chemokine CXCL1 | 1 | 2011 | 76 | 0.020 |
Why?
| | Cardiac Surgical Procedures | 1 | 2017 | 611 | 0.020 |
Why?
| | Vasoconstriction | 1 | 2012 | 216 | 0.020 |
Why?
| | Hypoglycemic Agents | 2 | 2011 | 1399 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 365 | 0.020 |
Why?
| | Benzamides | 1 | 2012 | 226 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2011 | 196 | 0.020 |
Why?
| | Cell Lineage | 1 | 2012 | 378 | 0.020 |
Why?
| | Snail Family Transcription Factors | 1 | 2010 | 18 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1505 | 0.020 |
Why?
| | Models, Animal | 1 | 2011 | 392 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2010 | 83 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2012 | 514 | 0.020 |
Why?
| | Matrix Metalloproteinases | 1 | 2010 | 95 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2011 | 310 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2011 | 389 | 0.020 |
Why?
| | Spleen | 1 | 2011 | 508 | 0.020 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2008 | 65 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2010 | 451 | 0.020 |
Why?
| | Sulindac | 1 | 2007 | 16 | 0.020 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2007 | 45 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2008 | 196 | 0.020 |
Why?
| | Metabolomics | 1 | 2013 | 733 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2008 | 162 | 0.020 |
Why?
| | Pyridines | 1 | 2012 | 609 | 0.020 |
Why?
| | Culture Media | 1 | 2007 | 161 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2007 | 302 | 0.020 |
Why?
| | Prognosis | 1 | 2016 | 4329 | 0.020 |
Why?
| | Transgenes | 1 | 2007 | 190 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 2007 | 167 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1217 | 0.010 |
Why?
| | Respiratory Mucosa | 1 | 2008 | 322 | 0.010 |
Why?
| | Genes, jun | 1 | 2005 | 9 | 0.010 |
Why?
| | CCAAT-Enhancer-Binding Protein-delta | 1 | 2005 | 6 | 0.010 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2005 | 37 | 0.010 |
Why?
| | Heterotrimeric GTP-Binding Proteins | 1 | 2005 | 11 | 0.010 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2005 | 19 | 0.010 |
Why?
| | Blood Pressure | 1 | 2012 | 1782 | 0.010 |
Why?
| | Genetic Markers | 1 | 2005 | 338 | 0.010 |
Why?
| | Genotype | 1 | 2008 | 1857 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2005 | 372 | 0.010 |
Why?
| | Heparin Lyase | 1 | 2003 | 5 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2007 | 2028 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 751 | 0.010 |
Why?
| | Cattle | 1 | 2004 | 946 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2003 | 855 | 0.010 |
Why?
| | Binding Sites | 1 | 2003 | 1311 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 2003 | 523 | 0.010 |
Why?
| | Bromodeoxyuridine | 1 | 1999 | 77 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 1999 | 318 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1999 | 335 | 0.010 |
Why?
| | Muscle Development | 1 | 1999 | 112 | 0.010 |
Why?
| | Models, Biological | 1 | 2003 | 1764 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1482 | 0.010 |
Why?
| | Gestational Age | 1 | 1999 | 989 | 0.010 |
Why?
| | DNA | 1 | 1999 | 1437 | 0.010 |
Why?
|
|
Weiser-Evans's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|